search
Back to results

Physical Activity Intervention for Gestational Diabetes (GDM)

Primary Purpose

Gestational Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ankle weights (2.5 pounds [1.1 kg]/ankle)
Control
Sponsored by
Sarah Keim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Gestational Diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18+ years
  • Diagnosed with GDM in current pregnancy
  • English language ability adequate for participation
  • Plan to remain in the area for study duration
  • Ability to provide informed consent

Exclusion Criteria:

  • Prior Type 1 or Type 2 diabetes
  • Pregnant with multiples (e.g., twin, triplets, etc.)
  • Premature infant [<35 completed weeks gestation (assessed after delivery, before randomization)]
  • Heart disease, serious illness, or conditions that may impede or prohibit participation in either study arm
  • Pre-pregnancy BMI <18.5 (underweight)
  • Live outside 35 mile radius of Ohio State University
  • Woman is an appointed surrogate
  • Infant will be adopted after delivery

Sites / Locations

  • Nationwide Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intervention

Control

Arm Description

Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.

All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.

Outcomes

Primary Outcome Measures

Weight loss
Postpartum weight loss will be defined as weight change from initial weigh-in at NCH Visit 1 to final weigh-in at NCH Visit 2. Weight will be measured in person using the Tanita.

Secondary Outcome Measures

Body Fat %
Percent body fat will be defined as the change in initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. Percent body fat will be measured in person using the Tanita.
BMI
BMI will be defined as the change from initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. BMI will be measured using the Tanita for weight and obstetric medical record for height.
Waist-hip Ratio
Waist circumference (cm) will be assessed at the middle point between the ribs and the iliac crest, with the participant standing. Hip circumference (cm) will be measured at the widest circumference of the buttocks. Change in circumference will be defined as the change from initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. Waist-hip ratio will be measured in person using metric cloth tape.
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Oral Glucose Tolerance Test (OGTT)
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. A fasting 2-hour, 75g OGTT will be conducted during both NCH visits. Glucose tolerance will be measured in mg/dL.
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: HOMA
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Insulin sensitivity (β-cell function) will be measured using the Matsuda index and HOMA-IR. Matsuda index score and HOMA-IR will be determined based on insulin values (μU/mL) and glucose values (mg/dL) obtained from the OGTT.
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Hemoglobin A1c (HbA1c)
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. HbA1c will be analyzed as a percentage.
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Leptin
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Fasting serum leptin will be measured in ng/mL.
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: High sensitivity c-reactive protein (hs-CRP)
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. hsCRP will be measured in mg/L.
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Adiponectin
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Adiponectin will be measured in µg/mL.
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Lipid Panel
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Lipids will be analyzed including total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides. Lipids will be measured in mg/dL.

Full Information

First Posted
September 5, 2018
Last Updated
July 19, 2022
Sponsor
Sarah Keim
Collaborators
Ohio Department of Health, Ohio State University, American Diabetes Association
search

1. Study Identification

Unique Protocol Identification Number
NCT03664089
Brief Title
Physical Activity Intervention for Gestational Diabetes
Acronym
GDM
Official Title
Physical Activity Intervention for Gestational Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
September 10, 2018 (Actual)
Primary Completion Date
February 22, 2022 (Actual)
Study Completion Date
July 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Sarah Keim
Collaborators
Ohio Department of Health, Ohio State University, American Diabetes Association

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Gestational diabetes mellitus (GDM) portends an immediate, increased risk for Type 2 diabetes mellitus (T2DM). The increased risk associated with having GDM is compounded by excess weight retention. Therefore, the weeks and months immediately after a GDM-complicated pregnancy present an optimal window to initiate lifestyle changes to prevent or delay T2DM. The long-term goal is to prevent T2DM among women with GDM. This study's objective is to evaluate the efficacy of a novel, yet simple, activity-boosting intervention on weight loss among women with GDM.
Detailed Description
Gestational diabetes mellitus (GDM) portends an immediate, increased risk for Type 2 diabetes mellitus (T2DM). The increased risk associated with having GDM is compounded by excess weight retention, a common issue after any pregnancy. Considering excess weight is the best predictor of developing T2DM, the weeks and months immediately after a GDM-complicated pregnancy present an optimal window to initiate lifestyle changes to prevent or delay T2DM. The long-term goal is to prevent T2DM among women with GDM. This study's objective is to evaluate the efficacy of a novel, yet simple, activity-boosting intervention on weight loss among women with GDM in a parallel two-arm randomized controlled trial (n=80 women/arm, N=160). The intervention uses ankle weights (2.5 pounds [1.1 kg]) worn on each ankle during routine daily activities (e.g., cleaning, cooking, child care) to increase energy expenditure. The central hypothesis, based on existing literature and preliminary data, is that postpartum women with GDM will adopt an intervention that requires minimal additional time outside of their daily activities. We anticipate that this will result in additional weight loss that is clinically significant when compared with controls who only receive standard information on recommended physical activity. The rationale for the proposed research is that once an intervention that both improves T2DM factors and is easily adopted by women with GDM is known, early intervention specific to this restricted timeframe can be implemented.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
75 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
Intervention Type
Behavioral
Intervention Name(s)
Ankle weights (2.5 pounds [1.1 kg]/ankle)
Intervention Description
Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
Intervention Type
Behavioral
Intervention Name(s)
Control
Intervention Description
Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
Primary Outcome Measure Information:
Title
Weight loss
Description
Postpartum weight loss will be defined as weight change from initial weigh-in at NCH Visit 1 to final weigh-in at NCH Visit 2. Weight will be measured in person using the Tanita.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary Outcome Measure Information:
Title
Body Fat %
Description
Percent body fat will be defined as the change in initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. Percent body fat will be measured in person using the Tanita.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
BMI
Description
BMI will be defined as the change from initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. BMI will be measured using the Tanita for weight and obstetric medical record for height.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Waist-hip Ratio
Description
Waist circumference (cm) will be assessed at the middle point between the ribs and the iliac crest, with the participant standing. Hip circumference (cm) will be measured at the widest circumference of the buttocks. Change in circumference will be defined as the change from initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. Waist-hip ratio will be measured in person using metric cloth tape.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Oral Glucose Tolerance Test (OGTT)
Description
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. A fasting 2-hour, 75g OGTT will be conducted during both NCH visits. Glucose tolerance will be measured in mg/dL.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: HOMA
Description
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Insulin sensitivity (β-cell function) will be measured using the Matsuda index and HOMA-IR. Matsuda index score and HOMA-IR will be determined based on insulin values (μU/mL) and glucose values (mg/dL) obtained from the OGTT.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Hemoglobin A1c (HbA1c)
Description
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. HbA1c will be analyzed as a percentage.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Leptin
Description
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Fasting serum leptin will be measured in ng/mL.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: High sensitivity c-reactive protein (hs-CRP)
Description
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. hsCRP will be measured in mg/L.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Adiponectin
Description
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Adiponectin will be measured in µg/mL.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Title
Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Lipid Panel
Description
Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Lipids will be analyzed including total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides. Lipids will be measured in mg/dL.
Time Frame
NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
We are assessing postpartum weight loss, therefore participants must be female to have the ability to give birth
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18+ years Diagnosed with GDM in current pregnancy English language ability adequate for participation Plan to remain in the area for study duration Ability to provide informed consent Exclusion Criteria: Prior Type 1 or Type 2 diabetes Pregnant with multiples (e.g., twin, triplets, etc.) Premature infant [<35 completed weeks gestation (assessed after delivery, before randomization)] Heart disease, serious illness, or conditions that may impede or prohibit participation in either study arm Pre-pregnancy BMI <18.5 (underweight) Live outside 35 mile radius of Ohio State University Woman is an appointed surrogate Infant will be adopted after delivery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah Keim, PhD, MA, MS
Organizational Affiliation
Nationwide Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34187391
Citation
Stith BJ, Buls SM, Keim SA, Thung SF, Klebanoff MA, Landon MB, Gabbe SG, Gandhi KK, Oza-Frank R. Moms in motion: weight loss intervention for postpartum mothers after gestational diabetes: a randomized controlled trial. BMC Pregnancy Childbirth. 2021 Jun 29;21(1):461. doi: 10.1186/s12884-021-03886-3.
Results Reference
derived

Learn more about this trial

Physical Activity Intervention for Gestational Diabetes

We'll reach out to this number within 24 hrs